

Attorney Docket No.: 930008-2208 (BOE0004US.NP)
Inventors: Klokke et al.
Serial No.: 10/577,569
Filing Date: February 27, 2008
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (canceled).

Claim 32 (previously presented): A process for the preparation of an aqueous dispersion for the preparation of a coating, comprising the steps of:

mixing together at least one fatty acid salt and at least one layer silicate to form a separating agent mixture, and

adding the separating agent mixture to an aqueous suspension of film-forming polymer(s).

Claim 33 (previously presented): The process of claim 32, wherein the film-forming polymer is a mixture of film-forming polymers.

Claim 34 (previously presented): The process of claim 32, wherein the film-forming polymer is a polyacrylate.

Claim 35 (previously presented): The process of claim 34, wherein the polyacrylate is a polymer based on acrylic acid, methacrylic acid, acrylic acid ester or methacrylic acid ester.

Claim 36 (previously presented): The process of claim 32, wherein the fatty acid salt is an alkali metal salt or

Attorney Docket No.: 930008-2208 (BOE0004US.NP)
Inventors: Klokke et al.
Serial No.: 10/577,569
Filing Date: February 27, 2008
Page 3

an alkaline earth metal salt or an aluminum salt of a fatty acid.

Claim 37 (withdrawn): The process of claim 36, wherein the alkali metal salt or alkaline earth metal salt is a sodium, potassium, magnesium or calcium behenate salt.

Claim 38 (previously presented): The process of claim 36, wherein the alkali metal salt or alkaline earth metal salt is a sodium, potassium, magnesium, calcium or aluminum stearate salt.

Claim 39 (withdrawn): The process of claim 36, wherein the alkaline earth metal salt is a magnesium salt of caprylic acid, capric acid, lauric acid or palmitic acid.

Claim 40 (currently amended): The process of claim 32, wherein the content of fatty acid salt is from 5 to 40% by weight or 10 to 30% by weight, in each case based on the dry weight of the film-forming polymer.

Claim 41 (previously presented): The process of claim 32, wherein the separating agent mixture comprises talcum, kaolinite, pyrophyllite, attapulgite, sepolite, muscovite, montmorillonite, bentonite, or vermiculite as layer silicate.

Claim 42 (previously presented): The process of claim 32, wherein the content of layer silicate is from 20 to 60% by weight or from 30 to 50% by weight, in each case based on the dry weight of the film-forming polymer.

Attorney Docket No.: 930008-2208 (BOE0004US.NP)
Inventors: Klokke et al.
Serial No.: 10/577,569
Filing Date: February 27, 2008
Page 4

Claim 43 (previously presented): The process of claim 32, further comprising applying the aqueous coating dispersion to an active-ingredient-containing core by spraying.

Claim 44 (previously presented): The process of claim 43, wherein the spray application step can be carried out using coating pans, fluidized bed, Accela-coater, dip tube or dip blade processes or pen coating.

Claim 45 (previously presented): The process of claim 43, wherein the active-ingredient-containing core is selected from capsules, tablets, pellets, granules, minitables or micropellets.

Claim 46 (withdrawn): The process of claim 43, wherein the active-ingredient-containing core is an active ingredient crystal.

Claim 47 (currently amended): The process of claim 45, wherein the pellets or micropellets ~~as active ingredient containing core~~ comprise an inert core which is coated with an active-ingredient-containing coating.

Claim 48 (withdrawn): The process of claim 45, wherein the micropellets are provided as multiple-unit-dosage form.

Claim 49 (withdrawn): The process of claim 47, wherein the micropellets are provided as multiple-unit-dosage form.

Attorney Docket No.: 930008-2208 (BOE0004US.NP)
Inventors: Klokke et al.
Serial No.: 10/577,569
Filing Date: February 27, 2008
Page 5

Claim 50 (withdrawn): The process of claim 48, wherein the multiple-unit dosage form is in the form of tablets or in capsules.

Claim 51 (withdrawn): The process of claim 49, wherein the multiple-unit dosage form is in the form of tablets or in capsules.

Claim 52 (previously presented): The process of claim 45, wherein the pellets, granules or minitabets are provided as multiple-unit-dosage form.

Claim 53 (previously presented): The process of claim 47, wherein the pellets are provided as multiple-unit-dosage form.

Claim 54 (previously presented): The process of claim 52, wherein the multiple-unit dosage form is in capsules.

Claim 55 (previously presented): The process of claim 53, wherein the multiple-unit dosage form is in capsules.

Claim 56 (previously presented): The process of claim 43, wherein the active ingredient is provided in admixture with pharmaceutically acceptable auxiliaries.

Claims 57-59 (canceled).

Claim 60 (previously presented): The process of claim 43, wherein the active ingredient is selected from metoprolol, bisoprolol, tramadol, morphine, oxycodone, and

Attorney Docket No.: 930008-2208 (BOE0004US.NP)
Inventors: Klokke et al.
Serial No.: 10/577,569
Filing Date: February 27, 2008
Page 6

hydrocodone, including stereo isomers and pharmaceutically acceptable salts, hydrates and solvates thereof.

Claim 61 (previously presented): The process of claim 43, wherein the active ingredient is metoprolol succinate.